All In Biotech

NDA 022503 · Primus Pharms

Metaxalone

Metaxalone · Oral · Muscle Relaxant

Last checked: Nov 19, 2026Latest source record: May 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jun 1, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9

0 Phase 3, 2 recruiting

FAERS reports

3,351

2,080 serious, 605 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 3, 2026.

Metaxalone Tablets, 640 mg, are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in adults and pediatric patients 13 years of age and older. Metaxalone Tablets, 640 mg, is a muscle relaxant, indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in adult and pediatric patients 13 years of age and older. ( 1 )

Mechanism: The mechanism of action of metaxalone as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions has not been established, but may be due to general CNS depression. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • METAXALONE · METAXALONE 640MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Metaxalone" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • completed suicide261
  • drug ineffective208
  • pain201
  • nausea199
  • fatigue198
  • headache172
  • toxicity to various agents164
  • fall159
  • diarrhoea135
  • dizziness123
  • dyspnoea122
  • death117

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200429
200546
200623
200728
200871
200923
201048
201175
2012105
2013172
2014159
2015283
2016322
2017240
2018270
2019366
2020342
2021179
2022153
202396
2024107
2025135
202679

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Metaxalone (Metaxalone)

2024 spending

$8.5M

Beneficiaries

27,984

71,567 claims

Per beneficiary

$304

$1.52 per unit

View as table
YearSpending
2020$13,465,766
2021$13,465,209
2022$11,496,332
2023$9,744,433
2024$8,495,416

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Primus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.